Ultragenyx Pharmaceutical (RARE) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Ultragenyx Pharmaceutical (RARE) overview

Ultragenyx Pharmaceutical (RARE) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 673m and operating profit of USD -535m; the year-end share price was 23.00 USD and market capitalisation was USD 2,222m. Ultragenyx Pharmaceutical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ultragenyx Pharmaceutical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD -80.0mFY 2025
Share price23.00 USDFY 2025 year end
RevenueUSD 673mFY 2025
Operating profitUSD -535mFY 2025
Net earningsUSD -575mFY 2025
Market capitalisationUSD 2,222mFY 2025 year end

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Its products and candidates include biologics, small molecules, gene therapies, and nucleic acid treatments. The company has approved therapies and clinical-stage candidates, and focuses on diseases with significant unmet medical needs. It serves patients through its commercial organization in multiple regions and third-party distributors in smaller markets.

Generate the Ultragenyx Pharmaceutical report

Ultragenyx Pharmaceutical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Ultragenyx Pharmaceutical and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Ultragenyx Pharmaceutical

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.